-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

Benzinga·10/07/2026 16:47:32
Listen to the news
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.